-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Adebrelimab (SHR-1316) is a humanized anti-PD-L1 monoclonal antibody independently developed by Hengrui Medicine .
Adebrelimab (SHR-1316) is a humanized anti-PD-L1 monoclonal antibody independently developed by Hengrui Medicine .
Lung cancer adebelimumab,
Patients with ES-SCLC without systemic therapy were randomized 1:1 to receive 4-6 cycles of treatment, one of which received Adebrelimab (20 mg/kg, intravenous, d1, q3w) + carboplatin (AUC 5 , d1, q3w) + etoposide (20mg/kg, intravenous, d1, q3w) treatment, the other group received placebo + carboplatin (AUC 5, d1, q3w) + etoposide (20mg/kg, intravenous injection, d1, q3w), followed by maintenance therapy with adebelimumab or placebo
462 patients were randomized and received treatment (230 in the Adebrelimab+chemotherapy group; 232 in the placebo+chemotherapy group)
As assessed by the Independent Review Committee (IRC), progression-free survival (PFS) was 5.
Progression-free survival (PFS) was 5.
This study demonstrated that the addition of adebrelimab to chemotherapy significantly improved OS with an acceptable safety profile, and data from this trial support this combination regimen as a new first-line treatment option for ES-SCLC
leave a message here